Healthcare provider profile · identity verified

Solmaz Rahmani, DO

Emergency Medicine · FLOSSMOOR, IL · NPI 1518379239

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	357	134
Atorvastatin Calcium	Atorvastatin Calcium	353	114
Amlodipine Besylate	Amlodipine Besylate	292	96
Levothyroxine Sodium	Levothyroxine Sodium	227	72
Losartan Potassium	Losartan Potassium	207	70
Metoprolol Succinate	Metoprolol Succinate	186	66
Pantoprazole Sodium	Pantoprazole Sodium	157	56
Gabapentin	Gabapentin	144	40
Furosemide	Furosemide	121	47
Albuterol Sulfate Hfa	Albuterol Sulfate	119	50
Hydrochlorothiazide	Hydrochlorothiazide	113	42
Montelukast Sodium	Montelukast Sodium	112	39
Simvastatin	Simvastatin	111	29
Potassium Chloride	Potassium Chloride	106	38
Metformin Hcl	Metformin Hcl	104	34
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	103	25
Lisinopril	Lisinopril	95	31
Fluticasone Propionate	Fluticasone Propionate	93	45
Eliquis	Apixaban	85	22
Prednisone	Prednisone	84	47
Alendronate Sodium	Alendronate Sodium	80	25
Alprazolam	Alprazolam	79	20
Omeprazole	Omeprazole	79	23
Meloxicam	Meloxicam	78	29
Tramadol Hcl	Tramadol Hcl	78	28
Glimepiride	Glimepiride	75	26
Carvedilol	Carvedilol	73	21
Vitamin D2	Ergocalciferol (Vitamin D2)	73	29
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	67	22
Clopidogrel	Clopidogrel Bisulfate	65	23
Sertraline Hcl	Sertraline Hcl	62	18
Escitalopram Oxalate	Escitalopram Oxalate	61	19
Mounjaro	Tirzepatide	60	14
Allopurinol	Allopurinol	56	18
Cephalexin	Cephalexin	55	50
Tizanidine Hcl	Tizanidine Hcl	51	22
Zolpidem Tartrate	Zolpidem Tartrate	50	18
Metoprolol Tartrate	Metoprolol Tartrate	49	17
Valsartan	Valsartan	49	16
Famotidine	Famotidine	47	15
Ozempic	Semaglutide	45	17
Amitriptyline Hcl	Amitriptyline Hcl	44	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	42	12
Ibuprofen	Ibuprofen	40	21
Tamsulosin Hcl	Tamsulosin Hcl	40	15
Trazodone Hcl	Trazodone Hcl	37	12
Enalapril Maleate	Enalapril Maleate	35	suppressed
Hydrocortisone	Hydrocortisone	35	16
Jardiance	Empagliflozin	35	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	34	28
Nystatin	Nystatin	34	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	33	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Clonidine Hcl	Clonidine Hcl	31	15
Chlorthalidone	Chlorthalidone	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Glipizide Er	Glipizide	30	suppressed
Methylprednisolone	Methylprednisolone	30	27
Hydralazine Hcl	Hydralazine Hcl	29	15
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	29	suppressed
Bupropion Xl	Bupropion Hcl	27	suppressed
Synthroid	Levothyroxine Sodium	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Azithromycin	Azithromycin	25	22
Clonazepam	Clonazepam	25	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	25	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	suppressed
Farxiga	Dapagliflozin Propanediol	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Glipizide	Glipizide	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	24	19
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	23	suppressed
Baclofen	Baclofen	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	13
Memantine Hcl	Memantine Hcl	23	suppressed
Ezetimibe	Ezetimibe	22	12
Fluconazole	Fluconazole	22	16
Klor-Con M20	Potassium Chloride	22	suppressed
Myrbetriq	Mirabegron	21	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	21	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Torsemide	Torsemide	20	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Pregabalin	Pregabalin	19	suppressed
Fenofibrate	Fenofibrate	18	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	suppressed
Linzess	Linaclotide	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	13
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Diazepam	Diazepam	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	12
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Estradiol	Estradiol	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	11
Januvia	Sitagliptin Phosphate	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Temazepam	Temazepam	12	suppressed
Dulera	Mometasone/Formoterol	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Topiramate	Topiramate	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error